519 OR641 is a novel dual antagonist antibody that targets LILRB1 and LILRB2 inhibitory receptors and promotes a Th1-like immune response

• Peter Probst,
• Kevin Green,
• Huyen Dinh,
• Francisco Zapata,
• Darbie Whitman,
• Tom Graddis,
• Myriam Bouchlaka,
• Meghan Zuck,
• Ray Fox,
• Tatyana Pisarenko,
• Elsa L Hay,
• Gajendra Naika,
• Jacob Heit,
• Kamal D Puri

Affiliations

Peter Probst

3Kineta, Inc., Seattle, WA, USA

Kevin Green

Division of Pulmonary, Critical Care and Sleep Medicine, University of Florida, Jacksonville, FL, USA

Huyen Dinh

OncResponse Inc., Seattle, WA, USA

Francisco Zapata

OncResponse Inc., Seattle, WA, USA

Darbie Whitman

OncResponse Inc., Seattle, WA, USA

Tom Graddis

OncResponse Inc., Seattle, WA, USA

Myriam Bouchlaka

OncResponse Inc., Seattle, WA, USA

Meghan Zuck

OncResponse Inc., Seattle, WA, USA

Ray Fox

OncResponse Inc., Seattle, WA, USA

Tatyana Pisarenko

OncResponse Inc., Seattle, WA, USA

Elsa L Hay

OncResponse Inc., Seattle, WA, USA

Gajendra Naika

OncResponse Inc., Seattle, WA, USA

Jacob Heit

OncResponse Inc., Seattle, WA, USA

Kamal D Puri

OncResponse Inc., Seattle, WA, USA